Inhibitors of Androgen Receptor Activation Function-2 (AF2) Site Identified through Virtual Screening
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
The androgen receptor (AR) is one of the most studied drug targets for the treatment of prostate cancer. However, all current anti-androgens directly interact with the AR at the androgen binding site, which is prone to resistant mutations, calling for new strategies of the AR inhibition. The current study represents the first attempt to use virtual screening to identify inhibitors of activation function-2 (AF2) of the human AR. By combining large-scale docking with experimental approaches, we were able to identify several small molecules that interact with the AF2 and effectively prevent the transcriptional activation of the AR. The crystallographic structure of one of these inhibitors in complex with the AR provides critical insight into the corresponding protein-ligand interactions and suitable for future hit optimization. Taken together, our results provide a promising ground for development of novel anti-androgens that can help to address the problem of drug resistance in prostate cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0306430 · Cited by 10,057
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705
Chemistry and Structural Biology of Androgen Receptor
Gao, W., Bohl, C. E., & Dalton, J. T. (2005) · Chemical Reviews · doi:10.1021/cr020456u · Cited by 528
Damber, J.-E., & Aus, G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60729-1 · Cited by 418
Culig, Z., Hoffmann, J., Erdel, M., Eder, I. E., Hobisch, A., Hittmair, A., Bartsch, G., Utermann, G., Schneider, M. R., Parczyk, K., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690684 · Cited by 409
Targeting the androgen receptor pathway in prostate cancer
Chen, Y., Sawyers, C. L., & Scher, H. I. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.07.005 · Cited by 389
Research works printed but not linked: 2
- Tilley W. D., 1994, Cancer Res., 54, 4096
- Irwin J., 2005, Abstr. Pap.–Am. Chem. Soc., 230, U1009
Cited by
Androgen receptor: structure, role in prostate cancer and drug discovery
Tan, M. E., Li, J., Xu, H. E., Melcher, K., & Yong, E.-L. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.18 · Cited by 943
Lack, N. A., Axerio-Cilies, P., Tavassoli, P., Han, F. Q., Chan, K. H., Féau, C., Leblanc, E., Guns, E. T., Guy, R. K., Rennie, P. S., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201098n · Cited by 148
Self-citationLi, H., Ban, F., Dalal, K., Leblanc, E., Frewin, K., Ma, D., Adomat, H., Rennie, P. S., & Cherkasov, A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500802j · Cited by 119
Self-citationBan, F., Dalal, K., Li, H., LeBlanc, E., Rennie, P. S., & Cherkasov, A. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00137 · Cited by 109
Self-citationBiolayer interferometry and its applications in drug discovery and development
Jug, A., Bratkovič, T., & Ilaš, J. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.117741 · Cited by 107
Munuganti, R. S. N., Leblanc, E., Axerio-Cilies, P., Labriere, C., Frewin, K., Singh, K., Hassona, M. D. H., Lack, N. A., Li, H., Ban, F., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3015712 · Cited by 88
Self-citationA magic drug target: Androgen receptor
Li, D., Zhou, W., Pang, J., Tang, Q., Zhong, B., Shen, C., Li, X., & Hou, T. (2018) · Medicinal Research Reviews · doi:10.1002/med.21558 · Cited by 91
Oleic acid is an endogenous ligand of TLX/NR2E1 that triggers hippocampal neurogenesis
Kandel, P., Semerci, F., Mishra, R., Choi, W. T.-S., Bajić, A., Baluya, D. L., Ma, L., Chen, K., Cao, A. C., Phongmekhin, T., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2023784119 · Cited by 90
Computer-Aided Ligand Discovery for Estrogen Receptor Alpha
Bafna, D., Ban, F., Rennie, P. S., Singh, K., & Cherkasov, A. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124193 · Cited by 76
“It has been demonstrated hat coactivator p300 can bind to th AF2 pocket v n in th absence of E2, by using th n tch sig ling thway [283].”
MethodInfluentialSelf-citationTargeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate Cancer
Lallous, N., Dalal, K., Cherkasov, A. R., & Rennie, P. S. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140612496 · Cited by 79
“identified several potent small molecule inhibitors selectively targeting the AR AF2 and the BF3 sites [10,13,118].”
BackgroundSelf-citationMunuganti, R. S. N., Hassona, M. D. H., Leblanc, E., Frewin, K., Singh, K., Ma, D., Ban, F., Hsing, M., Adomat, H. H., Lallous, N., et al. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.012 · Cited by 76
“BLI Assay The direct reversible interaction between small molecules and the AR was measured as previously described (Axerio-Cilies et al., 2011).”
MethodSelf-citationAllosteric Conversation in the Androgen Receptor Ligand-Binding Domain Surfaces
Grosdidier, S., Carbó, L. R., Buzón, V., Brooke, G., Nguyen, P., Baxter, J. D., Bevan, C., Webb, P., Estébanez-Perpiñá, E., & Fernández-Recio, J. (2012) · Molecular Endocrinology · doi:10.1210/me.2011-1281 · Cited by 69
Beyond the Ligand-Binding Pocket: Targeting Alternate Sites in Nuclear Receptors
Caboni, L., & Lloyd, D. G. (2012) · Medicinal Research Reviews · doi:10.1002/med.21275 · Cited by 67
Hsu, C.-L., Liu, J.-S., Wu, P.-L., Guan, H., Chen, Y., Lin, A.-C., Ting, H., Pang, S., Yeh, S.-D., Ma, W., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.06.009 · Cited by 58
D’Arrigo, G., Gianquinto, E., Rossetti, G., Cruciani, G., Lorenzetti, S., & Spyrakis, F. (2021) · Molecules · doi:10.3390/molecules26061613 · Cited by 63
Caboni, L., Kinsella, G. K., Blanco, F., Fayne, D., Jagoe, W. N., Carr, M. J., Williams, D. C., Meegan, M. J., & Lloyd, D. G. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201438f · Cited by 56
Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer
Carabet, L. A., Lallous, N., Leblanc, E., Ban, F., Morin, H., Lawn, S., Ghaidi, F., Lee, J., Mills, I. G., Gleave, M. E., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.09.023 · Cited by 52
“Findings reported in this study prompted us to leverage the full power of our in silico drug discovery platform that proved successful in targeting unconventional sites on protein surfaces and in yielding promising preclinical drug candidates for previously uncharted targets [59-67].”
ResultSelf-citationAndrogen receptor plasticity and its implications for prostate cancer therapy
Snow, O., Lallous, N., Singh, K., Lack, N. A., Rennie, P. S., & Cherkasov, A. R. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.05.001 · Cited by 58
Self-citationSchaduangrat, N., Anuwongcharoen, N., Charoenkwan, P., & Shoombuatong, W. (2023) · Journal of Cheminformatics · doi:10.1186/s13321-023-00721-z · Cited by 57
“In 2007, the first crystal structure of AF2 in complex with antagonist was solved and since then, several other structures have been elucidated [18, 19].”
BackgroundMethodTherapeutic Strategies to Target the Androgen Receptor
Xiang, W., & Wang, S. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00716 · Cited by 51
Molecular determinants of the recognition of ulipristal acetate by oxo-steroid receptors
Petit-Topin, I., Fay, M., Resche-Rigon, M., Ulmann, A., Gainer, E., Rafestin-Oblin, M. E., & Fagart, J. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.08.008 · Cited by 51
Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics
Matias-Barrios, V. M., Radaeva, M., Song, Y., Alperstein, Z., Lee, A. R., Schmitt, V., Lee, J., Ban, F., Xie, N., Qi, J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.633142 · Cited by 54
“Bio-Layer Interferometry Assays BLI assays were performed as we previously reported (33).”
MethodSelf-citationBadders, N. M., Korff, A., Miranda, H. C., Vuppala, P. K., Smith, R. B., Winborn, B. J., Quemin, E. R. J., Sopher, B. L., Dearman, J., Messing, J., et al. (2018) · Nature Medicine · doi:10.1038/nm.4500 · Cited by 45
“Recent advances in prostate cancer research have led to the discovery of many novel SARM compounds that specifically bind to and modulate coregulator binding to the AR AF2 domain 17-22 .”
Structure-based Virtual Screening and Identification of a Novel Androgen Receptor Antagonist
Song, C.-H., Yang, S., Park, E., Cho, S. H., Gong, E., Khadka, D. B., Cho, W., & Lee, K. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.379107 · Cited by 46
“These substantial advantages have made the VS approach increasingly valuable for the identification of novel lead scaffolds that bind to ligand-dependent receptors (30, 31).”
BackgroundAndrogen Receptor Gene Rearrangements: New Perspectives on Prostate Cancer Progression
Brand, L. J., & Dehm, S. M. (2013) · Current Drug Targets · doi:10.2174/1389450111314040005 · Cited by 43
Orphan nuclear receptors as drug targets for the treatment of prostate and breast cancers
Roshan‐Moniri, M., Hsing, M., Butler, M. S., Cherkasov, A. R., & Rennie, P. S. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.10.005 · Cited by 49
“There are no known endogenous ligands for ERRs, and the receptors are constitutively active due to the structure of the LBD that leaves the AF-2 site exposed and capable of binding coregulators in the absence of ligand binding.”
BackgroundInfluentialSelf-citationSakkiah, S., Kusko, R. L., Pan, B., Guo, W., Ge, W., Tong, W., & Hong, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00492 · Cited by 40
“Axerio-Cilies et al. (2011) experimentally proved that Met734 was pushed away from the AF2 site when bicalutamide binds AR.”
BackgroundIsomerization of bioactive acylhydrazones triggered by light or thiols
Zhang, Z., Le, G. N. T., Ge, Y., Tang, X., Chen, X., Ejim, L. J., Bordeleau, E., Wright, G. D., Burns, D. C., Tran, S., et al. (2023) · Nature Chemistry · doi:10.1038/s41557-023-01239-5 · Cited by 41
Self-citationSteroid receptor/coactivator binding inhibitors: An update
Skowron, K. J., Booker, K., Cheng, C., Creed, S. M., David, B. P., Lazzara, P. R., Lian, A., Siddiqui, Z., Speltz, T. E., & Moore, T. W. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110471 · Cited by 39
“virtually screened ~4 million compounds and discovered six potential candidates that were hypothesized to inhibit AR AF-2 (Axerio-Cilies et al., 2011).”
BackgroundGuo, Q., Zhong, M., Xu, H., Mao, X., Zhang, Y., & Lin, N. (2015) · Rejuvenation Research · doi:10.1089/rej.2014.1635 · Cited by 38
Sakkiah, S., Ng, H. W., Tong, W., & Hong, H. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2016.1192131 · Cited by 36
“The functional importance of the interaction between N- and C-terminals of AR is supported by naturally occurring loss of AR function due to the mutations in the activation function 2 (AF2) site where AR retains high-affinity androgen binding but is defective in AR FXXLF motif binding [58,59].”
BackgroundSakkiah, S., Wang, T., Zou, W., Wang, Y., Pan, B., Tong, W., & Hong, H. (2017) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15010025 · Cited by 38
“Binding of an antagonist in the LBP of AR had different conformational changes in the AF2 site of AR [76].”
BackgroundTian, X., He, Y., & Zhou, J. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00057 · Cited by 36
“…been identified to bind to these sites, and exhibiting potent activities in antagonizing the AR signaling, which inhibit the proliferation of AR dependent prostate cancer cells (Andersen et al., 2010; Axerio-Cilies et al., 2011; Ravindranathan et al., 2013; Li et al., 2014; Munuganti et al., 2014).”
Lallous, N., Leblanc, E., Munuganti, R. S. N., Hassona, M. D. H., Nakouzi, N. A., Awrey, S. J., Morin, H., Roshan‐Moniri, M., Singh, K., Lawn, S. O., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0354 · Cited by 32
“Biolayer interferometry (BLI) assay The direct reversible interactions between VPC-13566 or SGTA peptides and the AR LBD were measured as previously described (19).”
MethodSelf-citationChai, X., Sun, H., Zhou, W., Chen, C., Shan, L., Yang, Y., He, J., Pang, J., Liu, Y., Wang, X., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01938 · Cited by 29
L312, a novel PPARγ ligand with potent anti-diabetic activity by selective regulation
Xie, X., Zhou, X., Chen, W., Long, L., Li, W., Yang, X., Li, S., & Wang, L. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.09.027 · Cited by 30
Li, H., Hassona, M. D. H., Lack, N. A., Axerio-Cilies, P., Leblanc, E., Tavassoli, P., Kanaan, N., Frewin, K., Singh, K., Adomat, H. H., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0267 · Cited by 28
“The direct reversible interaction between small molecules and the androgen receptor was measured as previously described (24).”
MethodSelf-citationBiron, É., & Bédard, F. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.07.006 · Cited by 28
Singh, K., Munuganti, R. S. N., Leblanc, E., Lin, Y. L., Leung, E. Y., Lallous, N., Butler, M. S., Cherkasov, A. R., & Rennie, P. S. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0529-8 · Cited by 28
“In this study, we employed our established computational drug discovery pipeline [38-40] to identify more potent and selective inhibitors of ERα that specifically bind to the AF2 site and inhibit the interaction between ERα and its coactivator proteins.”
BackgroundMethodSelf-citationA review of the efficacy of prostate cancer therapies against castration-resistant prostate cancer
Zhang, S., Zhang, T., Kinsella, G. K., & Curtin, J. F. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104384 · Cited by 33
Advances in the computational development of androgen receptor antagonists
Hu, X., Chai, X., Wang, X., Duan, M., Pang, J., Fu, W., Li, D., & Hou, T. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.04.004 · Cited by 25
Androgen Receptor Modulators: A Marriage of Chemistry and Biology
McEwan, I. J. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.69 · Cited by 25
Structural Based Screening of Antiandrogen Targeting Activation Function-2 Binding Site
Liu, Y., Wu, M. Y., Wang, T., Xie, Y., Cui, X., He, L., He, Y., Li, X., Liu, M., Hu, L., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01419 · Cited by 19
“To date, several ligands have been identified to bind to the AF2 site, and exhibit potent activities in antagonizing the AR signaling, which inhibit the proliferation of AR dependent PCa cells (Andersen et al., 2010; Axerio-Cilies et al., 2011; Ravindranathan et al., 2013; Li et al., 2014; Munuganti et al., 2014).”
BackgroundZhang, C., Wu, J., Chen, Q., Tan, H., Huang, F., Guo, J., Zhang, X., Yu, H., & Shi, W. F. (2021) · Environment International · doi:10.1016/j.envint.2021.107009 · Cited by 19
Wu, Z., Zhan, Y., Wang, L., Tong, J., Zhang, L., Lin, M. M., Jin, X., Jiang, L., Lou, Y., & Qiu, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110556 · Cited by 15
Izquierdo, J., Jain, A., Abdulkadir, S. A., & Schiltz, G. E. (2018) · Synthesis · doi:10.1055/s-0037-1610669 · Cited by 15
Chemical Screening of Nuclear Receptor Modulators
Ishigami‐Yuasa, M., & Kagechika, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155512 · Cited by 16
Androgen receptor inhibitors in treating prostate cancer
Cole, R. N., Fang, Q., Matsuoka, K., & Wang, Z. (2024) · Asian Journal of Andrology · doi:10.4103/aja202494 · Cited by 15
“60 More recent developments have identified the molecules MDG506, 61 SPC002, 62 LHJ-647, 63 IMB-A6, 64 and T1-12.”
Martinez‐Ariza, G., & Hulme, C. (2015) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.15.20 · Cited by 14
Topçu, V., Ruhi, H. I., Şıklar, Z., Karabulut, H. G., Berberoğlu, M., Hacıhamdioğlu, B., Erdeve, Ş. S., Aycan, Z., Kendırcı, H. N. P., Öçal, G., et al. (2015) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2014-0500 · Cited by 14
Current and emerging approaches to noncompetitive AR inhibition
Riley, C. M., Elwood, J. M., Henry, M. C., Hunter, I., Lopez‐Fernandez, J. D., McEwan, I. J., & Jamieson, C. (2023) · Medicinal Research Reviews · doi:10.1002/med.21961 · Cited by 14
“The Cherkasov group has reported improvements to the modest potency and selectivity of BF‐3‐targeting antiandrogens.(49,73) Virtual screening efforts followed by cellular assays afforded 55 hits (>50% inhibition at 50 μM (A)”
BackgroundRecent advances in dietary androgen receptor inhibitors
Ren, L., Zhang, T., & Zhang, J. (2024) · Medicinal Research Reviews · doi:10.1002/med.22019 · Cited by 13
Chen, H., Yu, Y., Tian, X.-M., Wang, C.-L., Qian, Y., Deng, Z., Zhang, J., Lv, D., Zhang, H.-B., Shen, J., et al. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.11.029 · Cited by 13
Leblanc, E., Ban, F., Cavga, A. D., Lawn, S. O., Huang, C.-C. F., Mohan, S., Chang, M. E. K., Flory, M. R., Ghaidi, F., Lingadahalli, S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00681 · Cited by 14
Self-citationXu, X., Su, J. G., Bizzarri, A. R., Cannistraro, S., Liu, M., Zeng, Y., Chen, W. Z., & Wang, C. X. (2013) · BMC Structural Biology · doi:10.1186/1472-6807-13-16 · Cited by 13
“A recent study also revealed that several small molecules can bind to AF2 and then prevent the transcriptional activation of AR [19].”
BackgroundAllosteric Binding Sites On Nuclear Receptors: Focus On Drug Efficacy and Selectivity
Fischer, A., & Smieško, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020534 · Cited by 13
“In the literature, residues with a high degree of flexibility have been reported for the AR and include K720, M734, N727, F826, E829, and F837 [11,12].”
BackgroundMethodRecent Developments in Androgen Receptor Antagonists
Ran, F., Xing, H., Liu, Y., Zhang, D., Li, P., & Zhao, G. (2015) · Archiv der Pharmazie · doi:10.1002/ardp.201500187 · Cited by 11
Caboni, L., Gálvez-Llompart, M., Gálvez, J., Blanco, F., Rubio, J., Fayne, D., & Lloyd, D. G. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500324f · Cited by 11
Domínguez, M., Petkau‐Milroy, K., Vaz, B., Möcklinghoff, S., Folkertsma, S., Milroy, L. ‐., & Brunsveld, L. (2012) · MedChemComm · doi:10.1039/c2md20182h · Cited by 11
Caboni, L., Egan, B., Kelly, B., Blanco, F., Fayne, D., Meegan, M. J., & Lloyd, D. G. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400189m · Cited by 11
Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors
Radaeva, M., Li, H., Leblanc, E., Dalal, K., Ban, F., Ciesielski, F., Chow, B., Morin, H., Awrey, S. J., Singh, K., et al. (2022) · Cells · doi:10.3390/cells11182785 · Cited by 10
“Furthermore, this compound could effectively inhibit the activity of truncated ARVs [49], which play a critical role in the development of resistance to conventional anti-androgens (the corresponding findings around VPC14449 have been discussed previously in two publications) [15,39].”
Self-citationLee, T.-K., Ravindranathan, P., Sonavane, R., Raj, G. V., & Ahn, J. (2019) · Molecules · doi:10.3390/molecules24152783 · Cited by 10
“Several synthetic molecules targeting the interaction have been reported based on scaffolds like pyrimidines [23], dihydroperimidine [24], and diarylhydrazides [25].”
BackgroundNuclear Receptor Modulators — Current Approaches and Future Perspectives
Kronenberger, T., Keminer, O., Wrenger, C., & Windshügel, B. (2015) · InTech eBooks · doi:10.5772/59666 · Cited by 10
Chen, H., Zhang, J., Hu, P., Qian, Y., Li, J., & Shen, J. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115081 · Cited by 9
De-peptidising protein–protein interactions – big jobs for small molecules
Fayne, D. (2013) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2013.08.002 · Cited by 9
On the allosteric puzzle and pocket crosstalk through computational means
Aguti, R., Bernetti, M., Bosio, S., Decherchi, S., & Cavalli, A. (2023) · The Journal of Chemical Physics · doi:10.1063/5.0145364 · Cited by 8
Wang, F., Hu, S., Ma, D., Li, Q., Li, H., Liang, J., Chang, S., & Kong, R. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.800885 · Cited by 9
“The investigation of PDB structures show that except the native hormone-binding pocket, there are activation function 2 (AF2) pocket and binding function 3 (BF-3) pocket located on the ligand-binding domain (LBD) of the ER and AR (EstébanezPerpiñá et al., 2007; Axerio-Cilies et al., 2011; Lack et al., 2011; Buzón et a…”
BackgroundDoamekpor, S. K., Peng, P., Xu, R., Ma, L., Tong, Y., & Tong, L. (2023) · Acta Crystallographica Section F Structural Biology Communications · doi:10.1107/s2053230x23002224 · Cited by 8
Zhou, D., Xu, H. Z., Shen, X., Gu, R., Chen, Y., Chen, G., Li, P., Shi, H., Sun, X., & Xin, A. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.03.021 · Cited by 8
Cheminformatics Driven Development of Novel Therapies for Drug Resistant Prostate Cancer
Ban, F., Dalal, K., Leblanc, E., Morin, H., Rennie, P. S., & Cherkasov, A. R. (2018) · Molecular Informatics · doi:10.1002/minf.201800043 · Cited by 7
Self-citationAL-Zobaidy, M. J., Al-Hussaniy, H. A., & Al-tameemi, Z. S. (2024) · F1000Research · doi:10.12688/f1000research.110072.4 · Cited by 6
Li, Y., Jiao, T., Cheng, X., Liu, L., Zhang, M., Li, J., Wang, J., Hu, S., Li, C., Yu, T., et al. (2025) · Life Metabolism · doi:10.1093/lifemeta/loaf004 · Cited by 6
Gallastegui, N., & Estébanez‐Perpiñá, E. (2015) · Springer eBooks · doi:10.1007/978-3-319-18729-7_10 · Cited by 6
Hsu, C.-L., Liu, J.-S., Lin, T.-W., Chang, Y.-H., Kuo, Y., Lin, A.-C., Ting, H., Pang, S., Lee, L., Ma, W., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17843 · Cited by 6
“In addition to traditional antiandrogens, a number of peptides/molecules suppress AR-mediated functions by directly targeting the AF-2 cofactor-binding pocket [16, 25, 26, 27].”
BackgroundQi, Y., Chen, H., Chen, S., Shen, J., & Li, J. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.947065 · Cited by 6
Computational Assessment of Combination Therapy of Androgen Receptor-Targeting Compounds
Fischer, A., Häuptli, F., Lill, M. A., & Smieško, M. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c01194 · Cited by 6
Al-Hussaniy, H. A., Al-tameemi, Z. S., & AL-Zobaidy, M. J. (2022) · F1000Research · doi:10.12688/f1000research.110072.3 · Cited by 5
Molecular insights into the role of Estrogen Receptor Beta in Ecdysterone Mediated Anabolic Activity
Tariq, S. S., Sardar, M., Shafiq, M., Heinz, H., Nur-e-Alam, M., Ahmed, A., & Ul-Haq, Z. (2025) · PLoS One · doi:10.1371/journal.pone.0320865 · Cited by 4
“The structures of these proteins, retrieved from the Protein Data Bank with the PDB IDs 2YHD [12], 5WGD [13] and 4J26 [14] respectively, to serve as the preliminary point for further analysis.”
Qi, Y., Xue, B., Chen, S., Wang, W., Zhou, H., & Chen, H. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.1053675 · Cited by 4
“Binding mechanism experiments performed docking analysis of the three active pockets (LBP, AF2 and BF3) (Axerio-Cilies et al., 2011; Lack et al., 2011) in AR receptors using AutoDock software (Trott and Olson, 2010).”
Jiang, H., Chen, H., Wang, Y., Xu, H., & Chen, H. (2025) · Frontiers in Chemistry · doi:10.3389/fchem.2025.1557275 · Cited by 3
Joseph, R., & Binitha, R. N. (2020) · Materials Today Proceedings · doi:10.1016/j.matpr.2020.01.593 · Cited by 4
Bian, C., Wang, T., Wu, M. Y., Li, X., Zhao, S., Zheng, X., Liu, Y., Zhou, J., Chen, X., & Hu, L. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117712 · Cited by 2
Liao, J., Liao, J., Wang, Y., Wang, X., Chai, X., Wang, H., Xu, L., Shan, L., Xu, X., Fu, W., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02649 · Cited by 2
Xu, X., Xu, B., Wang, X., & Li, J. (2019) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2019.127128 · Cited by 1
Al-Hussaniy, H. A., Al-tameemi, Z. S., & AL-Zobaidy, M. J. (2022) · F1000Research · doi:10.12688/f1000research.110072.2 · Cited by 1
Ren, X. (2012) · cIRcle (University of British Columbia) · doi:10.14288/1.0073209
Li, H. (2015) · cIRcle (University of British Columbia) · doi:10.14288/1.0165754
Targeting the Androgen Receptor Signaling Axis
Li, H., Rennie, P. S., & Cherkasov, A. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12396-0
Self-citationAxerio-Cilies, P. (2017) · cIRcle (University of British Columbia) · doi:10.14288/1.0319183 · Cited by 3
Self-citationCrystal structure of 2-methyl-1H-perimidine, C12H10N2
Shi, X., Xiao, L., & Peng, P. (2020) · Zeitschrift für Kristallographie - New Crystal Structures · doi:10.1515/ncrs-2020-0175
Development of novel androgen receptor inhibitors to overcome castrate-resistant prostate cancer
Saraç, H., Cherkasov, A. R., & Lack, N. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821310-0.00007-3
Self-citationAl-Hussaniy, H. A., Al-tameemi, Z. S., & AL-Zobaidy, M. J. (2022) · F1000Research · doi:10.12688/f1000research.110072.1
“Adequacy of the natural ligands and androgen receptor inhibitors Ligands, both natural and those reported as inhibitors of AR activity, were subjected to adaptations with the Chimera USFC program for molecular interaction assays with the in-silico androgen receptor, adding hydrogen atoms and assigning Gastieger charge…”
MethodSchaduangrat, N., Anuwongcharoen, N., Charoenkwan, P., & Shoombuatong, W. (2024) · Figshare · doi:10.6084/m9.figshare.26587611
Chai, X., Hou, T., & Li, D. (2026) · Accounts of Chemical Research · doi:10.1021/acs.accounts.6c00261
Impact of a Novel Dehydroepiandrosterone Derivative on the Metabolism of RWPE-1 and LNCaP Cell Lines
Cabeza, M., Mejía, K., Heuze, Y., Morales-Pacheco, M., & Rodríguez‐Dorantes, M. (2026) · Oriental Journal Of Chemistry · doi:10.13005/ojc/420336
BindingDB Entry 50016950: Therapeutic Strategies to Target the Androgen Receptor.
BindingDB (2023) · UC San Diego · doi:10.7270/q2j1076h
BindingDB Entry 50014182: Development of 2-(5,6,7-Trifluoro-1
BindingDB (2022) · UC San Diego · doi:10.7270/q2736vqv
Metadata
- Authors
- Axerio-Cilies, P., Lack, N. A., Nayana, M. R. S., Chan, K. H., Yeung, A., Leblanc, E., Guns, E. S. T., Rennie, P. S., & Cherkasov, A.
- Affiliations
- University of British Columbia (CA)
- Corresponding author
- Cherkasov, Artem
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2011-08-29
- Volume
- 54
- Issue
- 18
- Pages
- 6197-6205
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1981652396
- Cited by
- 97
- References
- 26
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 5 · 2023: 5 · 2022: 11 · 2021: 6 · 2020: 7 · 2019: 5 · 2018: 8 · 2017: 4 · 2016: 3 · 2015: 10 · 2014: 8 · 2013: 9 · 2012: 6
- FWCI
- 8.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- androgen receptor, AF-2, prostate cancer, androgen receptor antagonists, drug resistance, transcriptional activation, protein-ligand interactions, virtual screening
- MeSH terms
- Androgen Antagonists, Binding Sites, Binding, Competitive, Humans, Ligands, Male, Models, Molecular, Prostatic Neoplasms, Receptors, Androgen, Transcription, Genetic, Molecular Structure, Transcriptional Activation, Databases, Factual, Crystallography, X-Ray, Drug Resistance, Neoplasm, Quantitative Structure-Activity Relationship, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.